The effect of topical bevacizumab on corneal neovascularization.
To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. Prospective, nonrandomized, masked observational case series. Ten eyes of 7 patients with corneal NV. Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. Corneal NV and changes in ophthalmic evaluations. Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.